Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during Long-Term Treatment of Chronic Hepatitis B: A Cross-Sectional Study

Table 1

Demographics of 92 patients on nucleotide analogues according to the severity of proximal renal tubular dysfunction (RTD).

	Normal; ()	Subclinical; proximal RTD ()	Overt; proximal RTD ()
Age (years)	54.0 ± 8.8	56.2 ± 12.5	60.2 ± 15.5	0.21
Male, (%)	43 (63.2)	11 (73.3)	5 (55.6)	0.65
Liver cirrhosis, (%)	21 (30.9)	4 (26.7)	3 (33.3)	0.93
Type 2 diabetes, (%)	12 (17.6)	3 (20.0)	2 (22.2%)	0.93
Hypertension, (%)	20 (29.4)	8 (53.3)	3 (33.3)	0.21
Duration of nucleotide analogue taking (months)	50.7 ± 28.9	65.1 ± 30.2	78.7 ± 20.2	0.01

Data are expressed as mean SD unless otherwise indicated.